Modern medicine has evolved so much so that sooner or later every breastfeeding mother needs to take it in one form or other. Medication that is present in mothers blood will transfer into her breast milk to some extent. Most drugs do so at low levels and pose no real risk to infants but then there are some exceptions. In This post will discuss whether Nebupent | Pentamidine Isethionate Inhalant is safe in breast-feeding or not.
What is Nebupent | Pentamidine Isethionate Inhalant used for?
NebuPent is indicated for the prevention of Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria: i. a history of one or more episodes of PJP ii. a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3. These indications are based on the results of an 18-month randomized, dose-response trial in high risk HIV-infected patients and on existing epidemiological data from natural history studies. The patient population of the controlled trial consisted of 408 patients, 237 of whom had a history of one or more episodes of PJP. The remaining patients without a history of PJP included 55 patients with Kaposi’s sarcoma and 116 patients with other AIDS diagnoses, ARC or asymptomatic HIV infection. Patients were randomly assigned to receive NebuPent via the Respirgard® II nebulizer at one of the following three doses: 30 mg every two weeks (n=135), 150 mg every two weeks (n=134) or 300 mg every four weeks (n=139). The results of the trial demonstrated a significant protective effect (p<0.01) against PJP with the 300 mg every four week dosage regimen compared to the 30 mg every two week dosage regimen. The 300 mg dose regimen reduced the risk of developing PJP by 50 to 70% compared to the 30 mg regimen. A total of 293 patients (72% of all patients) also received zidovudine at sometime during the trial. The analysis of the data demonstrated the efficacy of the 300 mg dose even after adjusting for the effect of zidovudine. The results of the trial further demonstrate that the dose and frequency of dosing are important to the efficacy of NebuPent prophylaxis in that multiple analyses consistently demonstrated a trend toward greater efficacy with 300 mg every four weeks as compared to 150 mg every two weeks. No dose-response was observed for reduction in overall mortality; however, mortality from PJP was low in all three dosage groups.
I am currently breastfeeding and I want to know if using Nebupent | Pentamidine Isethionate Inhalant is safe for my kid? Does it have any effect on milk production?
Active ingredient in Nebupent | Pentamidine Isethionate Inhalant is Pentamidine isethionate and based on our analysis of Pentamidine isethionate it appears that using Nebupent | Pentamidine Isethionate Inhalant is safe in breastfeeding. Below is analysis of Pentamidine isethionate while breastfeeding.
Nebupent | Pentamidine Isethionate Inhalant Breastfeeding Analsys
Pentamidine isethionate while Breastfeeding Safe
CAS Number: 100-33-4
Used in the treatment of leishmaniasis, african trypanosomiasis, and pneumocystiis. It does exist a recommended dosage for pediatric, or even neonatal, age. It has been included in the WHO Model List of Essential Drug and considered a suitable medication during breastfeeding.
I am nursing mother and I have already used Nebupent | Pentamidine Isethionate Inhalant, what should I do?
As usage of Nebupent | Pentamidine Isethionate Inhalant is mostly safe while breastfeeding hence there should not be any concern. In case of any change in behavior or health of your baby you should inform your health care provider about usage of Nebupent | Pentamidine Isethionate Inhalant else no further action is required.
My health care provider has asked me to use Nebupent | Pentamidine Isethionate Inhalant, what to do?
Definitely, Nebupent | Pentamidine Isethionate Inhalant is safe in lactation for baby. No wonder your doctor has recommended it.
If I am using Nebupent | Pentamidine Isethionate Inhalant, will my baby need extra monitoring?
No extra baby monitoring required while mother is using Nebupent | Pentamidine Isethionate Inhalant
Who can I talk to if I have questions about usage of Nebupent | Pentamidine Isethionate Inhalant in breastfeeding?
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week